Immunology follow-up after rituximab treatment in pediatric non Hodgkin lymfoma patients
Title in English | Immunology follow-up after rituximab treatment |
---|---|
Authors | |
Year of publication | 2018 |
Type | Conference abstract |
MU Faculty or unit | |
Citation | |
Description | Rituximab treatment leads to absolute transitional CD19+ B lymphocytopenia. IgG decrease could be delayed after the B cell recovery in the periphery. Clinical and laboratory sights of antibody secondary deficiency should be regularly monitored. |
Related projects: |